Basic Information
| LncRNA/CircRNA Name | HCP5 |
| Synonyms | NA |
| Region | GRCh38_6:31400702-31477506 |
| Ensemble | ENSG00000206337 |
| Refseq | NR_040662 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | triple negative breast cancer |
| ICD-0-3 | C50 |
| Methods | qRT-PCR, Western blotting, in vitro knockdown, Microarray assay etc. |
| Sample | The human TNBC cell line MDA-MB-231, MDA-MB-157, MDA-MB468, HCC1806 and HEK293 T cells, The DDP resistant MDA-MB-231 cells |
| Expression Pattern | down-regulated |
| Function Description | HCP5 were significantly upregulated in MDA-MB-231/DDP cells compared with MDA-MB-231 cells. Overexpression of HCP5 promoted DDP resistance in MDA-MB-231 cells by inhibiting PTEN expression. In contrast, inhibition of HCP5 reversed DDP resistance in MDA-MB-231/ DDP cells by upregulating PTEN. In vivo experiments confirmed that downregulation of HCP5 inhibited DDP resistance in TNBC xenograft. |
| Pubmed ID | 31028999 |
| Year | 2019 |
| Title | Long Noncoding RNA HCP5 Contributes to Cisplatin Resistance in Human Triple-Negative Breast Cancer via Regulation of PTEN Expression |
External Links
| Links for HCP5 | GenBank HGNC NONCODE |
| Links for triple negative breast cancer | OMIM COSMIC |